Search research articles
Contact Us
Filters
Showing results (121-130 of 129) with videos related to
Page
of 13
Sort By:
You have reached the last page of results.
This site can display upto 129 results.
The Journal of Infectious Diseases
|
March 1, 1993
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network
B S Graham, T J Matthews, R B Belshe, et al.
Vaccine
|
March 4, 2000
Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults
I M Gonzalez, R A Karron, M Eichelberger, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 12, 1998
Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant
R A Karron, D A Buonagurio, A F Georgiu, et al.
AIDS Research and Human Retroviruses
|
October 6, 1997
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group
M C Keefer, M Wolff, G J Gorse, et al.
The Journal of Infectious Diseases
|
April 1, 1997
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines
S Zolla-Pazner, C Alving, R Belshe, et al.
The Journal of Infectious Diseases
|
July 9, 1999
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
T G Evans, M C Keefer, K J Weinhold, et al.
Infection and Immunity
|
May 1, 1981
Evaluation of A/Alaska/6/77 (H3N2) cold-adapted recombinant viruses derived from A/Ann Arbor/6/60 cold-adapted donor virus in adult seronegative volunteers
B R Murphy, R M Chanock, M L Clements, et al.
The Journal of Infectious Diseases
|
February 1, 1996
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group
J R Mascola, S W Snyder, O S Weislow, et al.
The Journal of Infectious Diseases
|
May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group
M L Clements-Mann, K Weinhold, T J Matthews, et al.
Page
of 13
Search research articles
Search
Showing results (121-130 of 129) with videos related to
Sort By:
Page
of 13
You have reached the last page of results.
This site can display upto 129 results.
The Journal of Infectious Diseases
|
March 1, 1993
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network
B S Graham, T J Matthews, R B Belshe, et al.
Vaccine
|
March 4, 2000
Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults
I M Gonzalez, R A Karron, M Eichelberger, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 12, 1998
Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant
R A Karron, D A Buonagurio, A F Georgiu, et al.
AIDS Research and Human Retroviruses
|
October 6, 1997
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group
M C Keefer, M Wolff, G J Gorse, et al.
The Journal of Infectious Diseases
|
April 1, 1997
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines
S Zolla-Pazner, C Alving, R Belshe, et al.
The Journal of Infectious Diseases
|
July 9, 1999
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
T G Evans, M C Keefer, K J Weinhold, et al.
Infection and Immunity
|
May 1, 1981
Evaluation of A/Alaska/6/77 (H3N2) cold-adapted recombinant viruses derived from A/Ann Arbor/6/60 cold-adapted donor virus in adult seronegative volunteers
B R Murphy, R M Chanock, M L Clements, et al.
The Journal of Infectious Diseases
|
February 1, 1996
Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group
J R Mascola, S W Snyder, O S Weislow, et al.
The Journal of Infectious Diseases
|
May 21, 1998
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group
M L Clements-Mann, K Weinhold, T J Matthews, et al.
Page
of 13